Cabaletta Reports Drug-Free Responses in CAR-T Study
PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA) reported early clinical data showing two of four autoimmune disease patients treated with its experimental CAR-T therapy remained drug-free for six months …
Cabaletta Reports Drug-Free Responses in CAR-T Study Read More